A Phase 3 interventional study of TDF and FTC/TDF in Hepatitis B, sponsored by Gilead Sciences. Completed at 71 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-03-11.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 11th largest by enrollment, is one of 7 that started in 2008, is one of 13 in phase 3, and was the 12th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →
Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 13 · Phase 4 22
First in 2004; this study’s year is marked. 7 started in 2008.
This study's enrollment of 280 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 117 across the 50 interventional studies. Of the 37 that completed or were terminated, 17 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 50 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
34 studies in Hepatitis B, Chronic by Gilead Sciences: none open now, 2 under way, 1 of them phase 3. Of 31 finished, 24 (77%) have results posted.
Among the 34 studies in Hepatitis B, Chronic by Gilead Sciences, this one is the 5th largest by enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2008, is one of 8 in phase 3, and was the 16th registered.
Gilead Sciences’s Hepatitis B, Chronic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 34 in Hepatitis B, Chronic:
This tab as a report to print or save as PDF → With an account.
The aim of therapy for the treatment of chronic hepatitis B virus (HBV) is to maintain suppression of viral replication to prevent the emergence of complications, which requires long-term therapy. Durable suppression of viral replication is achieved in the treatment of chronic viral diseases by preventing of the emergence of drug-resistant mutations. The clinical guidelines for the management of lamivudine resistant patients are variable. Some recommend switching to another agent without cross-resistance, while others recommend adding on another agent without cross-resistance. Limited clinical data exists to demonstrate whether tenofovir disoproxil fumarate (tenofovir DF; TDF) is an effective monotherapy for lamivudine resistant patients or if it should be used as part of a combination therapy regimen.
This study is designed to evaluate the effectiveness, safety, and tolerability of tenofovir DF monotherapy versus emtricitabine (FTC)/tenofovir DF combination therapy in participants with chronic HBV with lamivudine resistance (presence of the rtM204I/V mutation with or without the rtL180M mutation) over a 240-week period. Participants in this study must be receiving lamivudine treatment at the time of enrollment.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
This study's enrollment of 280 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Browse Hepatitis B, Chronic studies →Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Compared within Hepatitis B, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis B. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TDF plus placebo to match FTC/TDF
Drug: TDF · Drug: FTC/TDF Placebo
FTC/TDF plus placebo to match TDF
Drug: FTC/TDF · Drug: TDF Placebo
Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily
Also known as: Viread®
Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily
Also known as: Truvada®
TDF placebo tablet administered orally once daily
FTC/TDF placebo tablet administered orally once daily
Percentage of Participants With HBV DNA < 400 Copies/mL at Week 96
Time frame: Week 96
Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 48, 144, 192, and 240
Time frame: Weeks 48, 144, 192, and 240
Percentage of Participants With HBV DNA < 169 Copies/mL at Weeks 48, 96, 144, 192, and 240
Time frame: Weeks 48, 96, 144, 192, and 240
HBV DNA Level at Weeks 48, 96, 144, 192, and 240
Time frame: Weeks 48, 96, 144, 192, and 240
Percentage of Participants With Normal ALT at Weeks 48, 96, 144, 192, and 240
Normal ALT was defined as having a value less than or equal to the ULN. The ULN was 43 U/L for males and 34 U/L for females aged 18 to \< 69, and 35 U/L for males and 32 U/L for females aged ≥ 69.
Time frame: Weeks 48, 96, 144, 192, and 240
Percentage of Participants With HBeAg Loss at Weeks 48, 96, 144, 192, and 240
The percentage of participants who were HBeAg positive at baseline and who had HBeAg Loss at the given time point was summarized. Loss of HBeAg was defined as change of detectable HBeAg from positive to negative.
Time frame: Baseline; Weeks 48, 96, 144, 192, and 240
Percentage of Participants With Seroconversion to Antibody Against HBeAg (Anti-HBe) at Weeks 48, 96, 144, 192, and 240
The percentage of participants who were HBeAg positive at baseline and who had seroconversion to anti-HBe at the given time point was summarized. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative to positive.
Time frame: Baseline; Weeks 48, 96, 144, 192, and 240
Percentage of Participants With HBV Surface Antigen (HBsAg) Loss at Weeks 48, 96, 144, 192, and 240
The percentage of participants with HBsAg Loss at the given time point was summarized. Loss of HBsAg was defined as change of detectable HBsAg from positive to negative.
Time frame: Baseline; Weeks 48, 96, 144, 192, and 240
Percentage of Participants With Seroconversion to Antibody Against HBV Surface Antigen (Anti-HBs) at Weeks 48, 96, 144, 192, and 240
The percentage of participants with seroconversion to anti-HBs at the given time point was summarized. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative to positive.
Time frame: Baseline; Weeks 48, 96, 144, 192, and 240
Percentage of Participants With Virologic Breakthrough at Weeks 48, 96, 144, 192, and 240
The percentage of participants with virologic breakthrough at the given time point was summarized. Virologic breakthrough was defined as having two consecutive 1.0 log10 or greater increases in serum HBV DNA from on-treatment nadir, or two consecutive HBV DNA values ≥ 400 copies/mL after being \< 400 copies/mL.
Time frame: Baseline; Weeks 48, 96, 144, 192, and 240
Percent Change From Baseline in Bone Mineral Density (BMD) of the Spine at Weeks 24, 48, 72, 96, 144, 192, and 240
BMD is calculated as grams per cubic centimeter (g/cm\^2); the mean (SD) percentage change is presented.
Time frame: Baseline; Weeks 24, 48, 72, 96, 144, 192, and 240
Percent Change From Baseline in BMD of the Hip at Weeks 24, 48, 72, 96, 144, 192, and 240
BMD is calculated as g/cm\^2; the mean (SD) percentage change is presented.
Time frame: Baseline; Weeks 24, 48, 72, 96, 144, 192, and 240
Development of Drug-resistant Mutations (DRMs)
The development of DRMs was summarized, either as development of new DRMs or enrichment of existing DRMs.
Time frame: Baseline to Week 240
Participants were enrolled at study sites in North America, Europe, and New Zealand. The first participant was screened on 30 September 2008. The last study visit occurred on 09 February 2015.
| Milestone | Tenofovir DF | FTC/Tenofovir DF |
|---|---|---|
| Started | 141 | 139 |
| Completed | 121 | 118 |
| Not completed | 20 | 21 |
| Withdrew: Investigator's discretion | 6 | 5 |
| Withdrew: Withdrew consent | 5 | 6 |
| Withdrew: Safety, tolerability, or efficacy reason | 3 | 4 |
| Withdrew: Lost to follow-up | 3 | 3 |
| Withdrew: Protocol violation | 2 | 3 |
| Withdrew: Study discontinued by sponsor | 1 | 0 |
| Milestone | Tenofovir DF | FTC/Tenofovir DF |
|---|---|---|
| Started | 38 | 37 |
| Completed | 12 | 19 |
| Not completed | 26 | 18 |
| Withdrew: Started commercial therapy | 25 | 17 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Withdrew consent | 1 | 0 |
| percentage of participants | Tenofovir DF | FTC/Tenofovir DF |
|---|---|---|
| Percentage of Participants With HBV DNA < 400 Copies/mL at Week 96 | 89.4 | 86.3 |
| percentage of participants | Tenofovir DF | FTC/Tenofovir DF |
|---|---|---|
| Week 48 | 81.6 | 84.2 |
| Week 144 | 87.2 | 84.9 |
| Week 192 | 86.5 | 85.6 |
| Week 240 | 83.0 | 82.7 |
| percentage of participants | Tenofovir DF | FTC/Tenofovir DF |
|---|---|---|
| Week 48 | 76.6 | 77.7 |
| Week 96 | 85.8 | 83.5 |
| Week 144 | 86.5 | 84.9 |
| Week 192 | 85.1 | 84.2 |
| Week 240 | 81.6 | 82.0 |
| log10 copies/mL | Tenofovir DF | FTC/Tenofovir DF |
|---|---|---|
| Week 48 (TDF: n=130; FTC/TDF: n=133) | 2.42 ± 0.542 | 2.48 ± 0.887 |
| Week 96 (TDF: n=132; FTC/TDF: n=127) | 2.29 ± 0.254 | 2.28 ± 0.241 |
| Week 144 (TDF: n=128; FTC/TDF: n=123) | 2.26 ± 0.173 | 2.29 ± 0.541 |
| Week 192 (TDF: n=126; FTC/TDF: n=119) | 2.25 ± 0.135 | 2.23 ± 0.027 |
| Week 240 (TDF: n=118; FTC/TDF: n=116) | 2.23 ± 0.052 | 2.26 ± 0.376 |
Normal ALT was defined as having a value less than or equal to the ULN. The ULN was 43 U/L for males and 34 U/L for females aged 18 to \< 69, and 35 U/L for males and 32 U/L for females aged ≥ 69.
| percentage of participants | Tenofovir DF | FTC/Tenofovir DF |
|---|---|---|
| Week 48 | 67.4 | 69.8 |
| Week 96 | 70.2 | 69.8 |
| Week 144 | 70.2 | 75.5 |
| Week 192 | 75.9 | 76.3 |
| Week 240 | 71.6 | 71.9 |
The percentage of participants who were HBeAg positive at baseline and who had HBeAg Loss at the given time point was summarized. Loss of HBeAg was defined as change of detectable HBeAg from positive to negative.
| percentage of participants | Tenofovir DF | FTC/Tenofovir DF |
|---|---|---|
| Week 48 | 9.2 | 5.9 |
| Week 96 | 15.4 | 13.2 |
| Week 144 | 23.1 | 17.6 |
| Week 192 | 21.5 | 14.7 |
| Week 240 | 24.6 | 19.1 |
The percentage of participants who were HBeAg positive at baseline and who had seroconversion to anti-HBe at the given time point was summarized. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative to positive.
| percentage of participants | Tenofovir DF | FTC/Tenofovir DF |
|---|---|---|
| Week 48 | 6.2 | 4.4 |
| Week 96 | 10.8 | 10.3 |
| Week 144 | 12.3 | 11.8 |
| Week 192 | 10.8 | 10.3 |
| Week 240 | 12.3 | 10.3 |
The percentage of participants with HBsAg Loss at the given time point was summarized. Loss of HBsAg was defined as change of detectable HBsAg from positive to negative.
| percentage of participants | Tenofovir DF | FTC/Tenofovir DF |
|---|---|---|
| Week 48 | 0.0 | 0.7 |
| Week 96 | 0.0 | 0.7 |
| Week 144 | 0.7 | 1.4 |
| Week 192 | 0.7 | 2.9 |
| Week 240 | 1.4 | 2.9 |
The percentage of participants with seroconversion to anti-HBs at the given time point was summarized. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative to positive.
| percentage of participants | Tenofovir DF | FTC/Tenofovir DF |
|---|---|---|
| Week 48 | 0.0 | 0.0 |
| Week 96 | 0.0 | 0.0 |
| Week 144 | 0.0 | 0.7 |
| Week 192 | 0.0 | 0.7 |
| Week 240 | 0.0 | 0.7 |
The percentage of participants with virologic breakthrough at the given time point was summarized. Virologic breakthrough was defined as having two consecutive 1.0 log10 or greater increases in serum HBV DNA from on-treatment nadir, or two consecutive HBV DNA values ≥ 400 copies/mL after being \< 400 copies/mL.
| percentage of participants | Tenofovir DF | FTC/Tenofovir DF |
|---|---|---|
| Week 48 (TDF: n=130; FTC/TDF: n=133) | 0.0 | 0.8 |
| Week 96 (TDF: n=132; FTC/TDF: n=127) | 0.0 | 0.0 |
| Week 144 (TDF: n=128; FTC/TDF: n=123) | 0.8 | 0.8 |
| Week 192 (TDF: n=126; FTC/TDF: n=119) | 0.8 | 0.0 |
| Week 240 (TDF: n=118; FTC/TDF: n=116) | 0.0 | 0.0 |
BMD is calculated as grams per cubic centimeter (g/cm\^2); the mean (SD) percentage change is presented.
| percentage change | Tenofovir DF | FTC/Tenofovir DF |
|---|---|---|
| % Change at Week 24 (TDF: n=132; FTC/TDF: n=127) | -1.74 ± 2.867 | -1.83 ± 2.565 |
| % Change at Week 48 (TDF: n=126; FTC/TDF: n=121) | -1.68 ± 3.094 | -1.73 ± 2.944 |
| % Change at Week 72 (TDF: n=123; FTC/TDF: n=119) | -1.35 ± 3.337 | -1.95 ± 2.977 |
| % Change at Week 96 (TDF: n=126; FTC/TDF: n=114) | -1.24 ± 3.761 | -1.72 ± 3.269 |
| % Change at Week 144 (TDF: n=123; FTC/TDF: n=110) | -1.36 ± 3.810 | -1.63 ± 3.591 |
| % Change at Week 192 (TDF: n=120; FTC/TDF: n=106) | -1.32 ± 4.237 | -1.60 ± 4.628 |
| % Change at Week 240 (TDF: n=115; FTC/TDF: n=102) | -0.83 ± 4.490 | -1.15 ± 5.130 |
BMD is calculated as g/cm\^2; the mean (SD) percentage change is presented.
| percentage change | Tenofovir DF | FTC/Tenofovir DF |
|---|---|---|
| % Change at Week 24 (TDF: n=130; FTC/TDF: n=127) | -0.71 ± 1.724 | -0.59 ± 1.835 |
| % Change at Week 48 (TDF: n=126; FTC/TDF: n=118) | -1.15 ± 2.120 | -1.00 ± 2.063 |
| % Change at Week 72 (TDF: n=121; FTC/TDF: n=115) | -1.59 ± 2.507 | -1.61 ± 2.525 |
| % Change at Week 96 (TDF: n=125; FTC/TDF: n=112) | -1.70 ± 2.617 | -1.77 ± 2.801 |
| % Change at Week 144 (TDF: n=120; FTC/TDF: n=107) | -2.02 ± 3.030 | -1.91 ± 3.281 |
| % Change at Week 192 (TDF: n=116; FTC/TDF: n=105) | -2.33 ± 3.190 | -2.41 ± 3.783 |
| % Change at Week 240 (TDF: n=111; FTC/TDF: n=100) | -2.46 ± 3.191 | -2.63 ± 3.872 |
The development of DRMs was summarized, either as development of new DRMs or enrichment of existing DRMs.
| participants | Tenofovir DF | FTC/Tenofovir DF |
|---|---|---|
| New tenofovir DF DRMs | 0 | 0 |
| Enrichment of tenofovir DF DRMs | 0 | 0 |
| New FTC DRMs | 0 | 0 |
| Enrichment of FTC DRMs | 0 | 1 |
Collected over Baseline through end of study drug treatment (average exposure 220 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tenofovir DF | — | 23/141 (16.3%) | 109/141 (77.3%) |
| FTC/Tenofovir DF | — | 21/139 (15.1%) | 105/139 (75.5%) |
| Event | Tenofovir DF | FTC/Tenofovir DF |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 1/141 | 3/139 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/141 | 2/139 |
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/141 | 1/139 |
| HaematuriaRenal and urinary disorders | 2/141 | 0/139 |
| Coronary artery stenosisCardiac disorders | 0/141 | 1/139 |
| Middle ear inflammationEar and labyrinth disorders | 0/141 | 1/139 |
| Tympanic membrane perforationEar and labyrinth disorders | 0/141 | 1/139 |
| Abdominal painGastrointestinal disorders | 0/141 | 1/139 |
| DiarrhoeaGastrointestinal disorders | 0/141 | 1/139 |
| GastritisGastrointestinal disorders | 1/141 | 1/139 |
| Event | Tenofovir DF | FTC/Tenofovir DF |
|---|---|---|
| NasopharyngitisInfections and infestations | 24/141 | 20/139 |
| HeadacheNervous system disorders | 23/141 | 20/139 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 10/141 | 18/139 |
| FatigueGeneral disorders | 14/141 | 15/139 |
| Back painMusculoskeletal and connective tissue disorders | 10/141 | 15/139 |
| InfluenzaInfections and infestations | 14/141 | 10/139 |
| CoughRespiratory, thoracic and mediastinal disorders | 12/141 | 13/139 |
| DiarrhoeaGastrointestinal disorders | 13/141 | 7/139 |
| Abdominal pain upperGastrointestinal disorders | 8/141 | 12/139 |
| NauseaGastrointestinal disorders | 12/141 | 11/139 |
| Age, Continuous(years) | Tenofovir DF | FTC/Tenofovir DF | Total |
|---|---|---|---|
| Mean | 47.1 ± 13.63 | 46.3 ± 13.56 | 46.7 ± 13.58 |
| Sex: Female, Male(Participants) | Tenofovir DF | FTC/Tenofovir DF | Total |
|---|---|---|---|
| Female | 37 | 32 | 69 |
| Male | 104 | 107 | 211 |
| Ethnicity (NIH/OMB)(Participants) | Tenofovir DF | FTC/Tenofovir DF | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 138 | 137 | 275 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race/Ethnicity, Customized(participants) | Tenofovir DF | FTC/Tenofovir DF | Total |
|---|---|---|---|
| Asian | 52 | 42 | 94 |
| Black or African American | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 3 | 3 |
| White | 83 | 89 | 172 |
| Other | 3 | 4 | 7 |
| Region of Enrollment(participants) | Tenofovir DF | FTC/Tenofovir DF | Total |
|---|---|---|---|
| Austria | 2 | 3 | 5 |
| Bulgaria | 2 | 5 | 7 |
| Canada | 47 | 43 | 90 |
| Czech Republic | 9 | 7 | 16 |
| Germany | 2 | 0 | 2 |
| Greece | 2 | 1 | 3 |
| Hungary | 4 | 3 | 7 |
| New Zealand | 7 | 10 | 17 |
| Poland | 13 | 19 | 32 |
| Romania | 17 | 14 | 31 |
| Serbia | 17 | 19 | 36 |
| Spain | 1 | 1 | 2 |
| Turkey | 15 | 13 | 28 |
| United States | 3 | 1 | 4 |
| ALT Normal at Baseline(participants) | Tenofovir DF | FTC/Tenofovir DF | Total |
|---|---|---|---|
| Abnormal | 79 | 83 | 162 |
| Normal | 62 | 56 | 118 |
| Hepatitis B Virus (HBV) DNA Level at Baseline(log_10 copies/mL) | Tenofovir DF | FTC/Tenofovir DF | Total |
|---|---|---|---|
| Mean | 6.40 ± 1.826 | 6.53 ± 1.968 | 6.46 ± 1.896 |
| HBV e Antigen (HBeAg) Status at Baseline(participants) | Tenofovir DF | FTC/Tenofovir DF | Total |
|---|---|---|---|
| Negative | 76 | 71 | 147 |
| Positive | 65 | 68 | 133 |
The record gives a start of Sep 2008, a primary completion of Nov 2011 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2013, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenofovir